Several biologic agents are expected to be approved for the treatment of rheumatoid arthritis in the next few years.

The FDA issues Early Communication of immunosuppressants' possible association with lymphoma.

FDA alerts clinicians to serious infections associated with the use of Enbrel

Because of cardiovascular and gastrointestinal risks, NSAIDS are no longer recommended for long-term use. No single drug or therapy is regarded as the ideal long-term treatment for osteoarthritis.

The FDA and Institute for Safe Medication Practices report that many drug errors are still occurring with Cerebyx because many hospital staffers are misreading the drug concentration.

Bristol-Myers Squibb granted approval for arthritis biologic Orencia.

Adalimumab approved for polyarticular juvenile idiopathic arthritis.

First generic alendronate sodium tablets approved

Injectable colchicine is removed from the market by FDA